Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Parkinson’s disease and related disorders

Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.

J R Bedarf; F Hildebrand; L P Coelho; S Sunagawa; M Bahram; F Goeser; P Bork; U Wüllner

Originally published in Genome medicine · 2017-04-28

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Parkinson's disease (PD) presently is conceptualized as a protein aggregation disease in which pathology involves both the enteric and the central nervous system, possibly spreading from one to another via the vagus nerves. As gastrointestinal dysfunction often precedes or parallels motor symptoms, the enteric system with its vast diversity of microorganisms may be involved in PD pathogenesis. Alterations in the enteric microbial taxonomic level of L-DOPA-naïve PD patients might also serve as a biomarker. Methods We performed metagenomic shotgun analyses and compared the fecal microbiomes of 31 early stage, L-DOPA-naïve PD patients to 28 age-matched controls. Results We found increased Verrucomicrobiaceae (Akkermansia muciniphila) and unclassified Firmicutes, whereas Prevotellaceae (Prevotella copri) and Erysipelotrichaceae (Eubacterium biforme) were markedly lowered in PD samples. The observed differences could reliably separate PD from control with a ROC-AUC of 0.84. Functional analyses of the metagenomes revealed differences in microbiota metabolism in PD involving the ẞ-glucuronate and tryptophan metabolism.

Conclusions

Our data revealed differences of colonic microbiota between PD patients and controls at an unprecedented detail not achievable through 16S sequencing: altered representation of several taxa including Eubacterium biforme, which has not been reported previously and might be limited to detection via metagenomics. The functional differences in the gut microbiota included ẞ-glucuronate and tryptophan degrading pathways. The findings point to a yet-unappreciated aspect of PD, possibly involving the intestinal barrier function and immune function in PD patients.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?